Florida Senate Committee Advances Kratom Consumer Protection Act

A Florida Senate committee has advanced a bill aimed at regulating kratom. On Wednesday, the Senate Commerce and Tourism Committee voted 8 to 1 in favor of Senate Bill 1734, known as the Florida Kratom Consumer Protection Act. If passed, this legislation would establish comprehensive statewide regulations for kratom processing and sales, ensuring consumer safety and product quality. (The Marijuana Herald)

The bill includes strict safety guidelines, prohibiting the addition of non-kratom substances and setting limits on the concentrations of mitragynine and 7-hydroxymitragynine. It also mandates clear labeling, including ingredients, serving sizes, and potential effects. Sales to individuals under 21 would be prohibited, and all kratom processors would need to register with the FDA and hold the necessary state permits. SB 1734 will now move to the Senate Agriculture, Environment, and General Government Appropriations Committee for further consideration.

States Grapple with Kratom Regulation Amid Federal Absence

With the federal government yet to take definitive action, individual states are increasingly wrestling with how to regulate kratom, a plant-derived substance used by some for pain relief and energy. The Pain News Network reports that states like Montana are considering measures to ban sales to minors and mandate specific product labeling.

The debate around kratom centers on its potential health effects and the risk of addiction. Proponents argue that kratom offers a natural alternative for managing pain, while opponents voice concerns about safety and the lack of standardized regulations. As states navigate these conflicting viewpoints, the future of kratom regulation remains uncertain.

Read the full story on Pain News Network.

Illinois Lawmakers to Hold Public Hearing on Kratom Regulation

Illinois lawmakers have scheduled a public hearing to discuss the “Kratom Consumer Protection Act,” a bill designed to regulate kratom products in the state. The proposed legislation, introduced by Representative Curtis Tarver, includes several key provisions. It would prohibit the sale of kratom to individuals under 21 and ban products that are appealing to children. Additionally, the bill would outlaw the sale of kratom products containing synthesized alkaloids and impose a 5% retail tax statewide. Violations could result in fines of up to $20,000. For more information on the bill and its potential impact, you can refer to similar discussions on kratom regulation. The hearing is a crucial step towards establishing stricter guidelines for kratom in Illinois.

Montana Debates Kratom Regulation Amid Federal Absence

Montana is grappling with how to regulate kratom, a plant-based substance marketed as a mood and energy enhancer with potential for addiction. With no federal oversight, the state is acting to address supply chain issues and safeguard consumers.

The “Kratom Consumer Protection Act,” drafted by the American Kratom Association, is under consideration in the Montana Legislature. The act seeks to ban sales to those under 18 and limit the products labeled as “kratom” based on the concentration of specific chemical elements. Other states have passed similar industry-supported legislation.

Concerns remain about whether the proposed bill prioritizes public health or commercial interests. According to a report by NBC Montana, the bill’s success depends on the state’s capacity to regulate the industry and the integrity of retailers in product testing and advertising.

Missouri House Committee Advances Kratom Consumer Protection Act

The Missouri House Emerging Issues Committee has unanimously approved the Kratom Consumer Protection Act (HB 1037) with a 13-0 vote, marking a significant step toward regulating kratom products in the state. The bill aims to ensure consumer safety by implementing strict guidelines on labeling, sales, and product contents.

Kratom, a plant-derived substance from Southeast Asia, is often used for pain relief and anxiety management but has faced legal scrutiny due to inconsistent product quality and potency. If passed, HB 1037 would require accurate labeling of alkaloid content, ban sales to individuals under 21, and prohibit adulterated or synthetic kratom products. Violators could face fines or misdemeanor charges, while harmed consumers may pursue legal action.

With bipartisan support, the bill now moves to the full House for further consideration. For more details, visit The Marijuana Herald.

Jones County Supervisors Debate Kratom Regulation

The Jones County Board of Supervisors recently discussed the regulation of kratom, a controversial herbal product derived from Southeast Asia, during their March 4 meeting. While no official decision was made, the board acknowledged growing concerns over kratom’s potential health risks and its availability in local stores.

Kratom, often marketed as a natural remedy for pain and opioid withdrawal, has sparked debate nationwide due to its stimulant- and opioid-like effects. Critics argue it is addictive and dangerous, while supporters claim it can be a valuable tool for managing chronic conditions.

The board is considering options, including restrictions or an outright ban, but emphasized the need for further research and public input before proceeding. This discussion reflects broader legislative efforts across Mississippi to regulate kratom use and sales.

For more details, visit WDAM.

FDA Pilot Study Finds Kratom Leaf “Well-Tolerated” in Controlled Dosing

A recent FDA-led pilot study evaluating kratom’s safety revealed the botanical was “well tolerated” in single doses up to 12 grams under clinical conditions. The trial, involving 40 healthy participants with no substance abuse history, tested escalating doses of encapsulated kratom leaf powder. While higher doses (8–12 grams) caused transient nausea—attributed to the bulk of ingesting up to 24 capsules—researchers observed no severe adverse effects beyond minor pupil dilation.

Christopher McCurdy, a University of Florida medicinal chemist and study co-author, noted the findings open doors for further research into kratom’s therapeutic potential, particularly for pain management and opioid withdrawal. The study used rigorously tested kratom from Super Speciosa, a supplier advocating for industry regulation and standardized manufacturing practices.

FDA emphasized the need for additional studies to assess risks linked to commercial kratom products, including extracts with concentrated alkaloids. Advocates hope the results prompt balanced oversight rather than outright bans. For full details, read the original SupplySide SJ report.

Colorado Issues First Licenses for Psilocybin Businesses, Legal Access Expected by Spring

Colorado has taken a major step in its journey toward regulated psilocybin-assisted therapy by issuing the first licenses to individuals in the emerging psilocybin industry. The state’s Department of Revenue’s Natural Medicine Division approved seven applications for cultivation and healing centers, along with one additional license for a local industry worker. While these approvals mark significant progress, businesses must still secure official licenses before operations can begin.

This milestone follows the passage of Proposition 122, also known as the Natural Medicine Health Act, in November 2022. The act decriminalized personal use and possession of psilocybin for adults over 21 and set up a framework for regulated therapies and licensed facilities. Colorado joins Oregon as one of the first states to legalize and regulate psilocybin treatments. Regulators anticipate public access to these therapies as early as spring.

For more details, visit The Marijuana Herald.

New York Senators Introduce Bill to Legalize Psilocybin Therapy in 2025

New York lawmakers are making strides toward mental health reform with a newly proposed bill to legalize psilocybin-assisted therapy. Introduced by Senator Nathalia Fernandez (D) and five co-sponsors, the legislation aims to provide certified psilocybin treatment for patients with qualifying conditions. This therapy could take place in clinical settings or even at patients’ homes if they are unable to travel.

The bill also includes a Psilocybin Assisted Therapy (PAT) grant program, allocating $5 million to ensure access for veterans, first responders, and low-income individuals. Additionally, the state Department of Agriculture and Markets would oversee a pilot program to cultivate psilocybin mushrooms, aiming to reduce costs.

Senator Fernandez emphasized the urgent need for alternative mental health treatments, stating that the legislation is a response to an ongoing mental health crisis. For more details, read the full article on Marijuana Moment.

Global Experts Convene at UF for Fourth International Kratom Symposium

The Fourth International Kratom Symposium, held February 4-7 at the University of Florida College of Pharmacy’s Orlando campus, brought together nearly 100 researchers, regulators, and industry leaders from around the world. This invitation-only event highlighted the latest advancements in kratom research and explored strategies for responsible regulation of the Southeast Asian plant known for its potential therapeutic benefits.

Keynote speaker Dr. Jack Henningfield of Johns Hopkins University praised the remarkable growth in kratom-related research, noting a surge in publications from 22 in 2015 to over 140 in 2024. The symposium featured over 40 presentations on topics such as clinical studies, quality standards, and regulatory frameworks.

UF’s leadership in kratom research was emphasized by Dr. Oliver Grundmann, who highlighted the university’s role in advancing global collaboration. For more details on this event, visit UF College of Pharmacy.

Elk Grove Village Bans Sale of Kratom

Elk Grove Village trustees have voted to prohibit the sale of kratom, a substance commonly found in smoke and vape shops, marking the latest step in the village’s efforts to regulate controversial products. The ban, which takes effect on Friday, February 21, follows a similar restriction on low-dose THC products enacted earlier in 2023.

Kratom, derived from the leaves of a Southeast Asian tree, occupies a legal gray area. While the U.S. Drug Enforcement Administration (DEA) has labeled it a “Drug and Chemical of Concern,” it is not currently regulated under the Controlled Substances Act. The DEA notes that kratom can produce stimulant effects at low doses and sedative effects at higher doses, with risks of addiction and psychosis in some cases.

Mayor Craig Johnson acknowledged kratom’s growing controversy and noted that many municipalities nationwide have already banned it. For more details, visit the full report at Journal & Topics.

Mississippi House Passes Bill to Regulate Kratom Sales

The Mississippi House of Representatives has unanimously passed a bill to restrict kratom sales to individuals aged 21 and older while banning synthetic kratom products. House Bill 1077, authored by Rep. Lee Yancey, aims to address concerns about the herbal substance, which critics claim is addictive and produces opioid-like effects.

The legislation requires proof of age for purchases and mandates that retailers keep kratom behind the counter. It also imposes fines on underage buyers and sellers. Synthetic kratom extracts, which contain high concentrations of the psychoactive compound 7-hydroxymitragynine, are prohibited under the bill.

Advocates argue that kratom can help manage opioid withdrawal and chronic pain, while opponents push for stricter regulation or outright bans. The bill now moves to the Senate for consideration. For more details, visit Mississippi Today.

Mississippi Lawmakers Take Steps Toward Responsible Kratom Regulation

Mississippi’s House Drug Policy Committee is making strides toward regulating kratom, an herbal supplement with both advocates and critics. Committee Chair Stacey Wilkes (R) introduced House Bill 1121 to classify kratom as a Schedule III substance, aiming to balance public safety with informed decision-making. The bill seeks to address concerns about kratom’s addictive potential while ensuring lawmakers are educated on its effects.

During a recent hearing, state health leaders highlighted kratom’s ability to bind to opioid receptors, providing pain relief but also raising risks of dependency. Advocates, however, emphasize its role in harm reduction and as a natural alternative for managing chronic pain.

The legislation has passed the Drug Policy Committee and awaits further review. By fostering informed dialogue, Mississippi is taking proactive steps to regulate kratom responsibly. For more details, visit the full article on the Magnolia Tribune here.

Batavia Residents Push Back Against Proposed Kratom and CBD Sales Ban

A proposed ordinance to ban the sale of kratom, Delta-8 THC, and other synthetic drugs in Batavia, Illinois, faced strong opposition from residents and business owners during a City Council meeting on January 28. The ordinance, introduced by Police Chief Eric Blowers, cited public health risks associated with these substances, including hallucinations, seizures, and even fatalities. Blowers also referenced a 2021 fatal traffic accident involving a driver who tested positive for kratom.

Despite these concerns, local merchants argued the ban was overly broad. Cheryl Cryer, owner of Urban Apothecary, defended her store’s CBD products, presenting over 100 letters from customers opposing the measure. Distributor Brent King likened whole-leaf kratom to poppy seeds—safe in natural form but dangerous when synthesized.

After nearly an hour of public comments, the council unanimously tabled the ordinance, citing enforcement challenges. For more details, visit Shaw Local.

Massachusetts Lawmakers Push for Psychedelics Reform with 12 New Bills

Massachusetts legislators have introduced 12 psychedelics-related bills following the defeat of the 2024 ballot initiative to legalize and decriminalize psychedelic substances. The proposals, filed ahead of last week’s legislative deadline, aim to advance therapeutic access, decriminalization, and harm reduction strategies.

Key measures include pilot programs for psilocybin-assisted therapy targeting mental health conditions like PTSD and depression. Notable bills, such as HD 4017 and HD 4196, propose establishing treatment centers and regulated access programs. Other initiatives focus on decriminalizing small-scale possession and addressing racial justice in drug policy.

Advocates like Jamie Morey and Graham Moore, leaders of Massachusetts for Mental Health Options, have emphasized the public’s continued support for psychedelics reform despite the ballot defeat. They hope these legislative efforts will inspire broader advocacy across the state.

For more details on these proposals, visit Marijuana Moment.

Colorado’s Psilocybin Legalization Sparks Debate Amid Therapy Rollout

Colorado has officially entered the forefront of psychedelic legalization, becoming one of the first states to allow psilocybin-assisted therapy. Following the passage of Proposition 122 in 2022, the state is now licensing “healing centers” where individuals can access supervised psilocybin sessions. Advocates hail this as a groundbreaking step toward alternative treatments for mental health conditions like PTSD and depression, particularly for veterans.

However, the move has not been without controversy. Critics, including some conservative groups, argue that the state is moving too quickly and raising concerns about potential misuse and societal impacts. Despite this pushback, proponents emphasize the therapeutic potential of psilocybin when administered in controlled environments.

As Colorado navigates this new terrain, it joins Oregon in shaping the future of psychedelic therapy in the U.S., setting a precedent for other states considering similar measures. For more details, see the full article on Newsweek.

Georgia Enacts New Regulations for Kratom Sales and Production

Georgia Governor Brian Kemp has signed a new law introducing stricter regulations on the sale and production of kratom, a popular herbal supplement derived from the Mitragyna speciosa tree. The legislation, which took effect this month, establishes key consumer safety measures, including an age restriction of 21 years for purchasing kratom, mandatory product labeling standards, and limits on the concentration of active alkaloids in kratom products.

The law aims to address growing concerns about unregulated kratom products while ensuring safe access for consumers. Advocates of the legislation view it as a balanced approach that prioritizes public health without resorting to an outright ban. Georgia joins several other states that have implemented similar regulatory frameworks under the Kratom Consumer Protection Act model.

For more details on Georgia’s new kratom legislation, visit AP News.

New York Lawmakers Push for Psilocybin Therapy Legalization in 2025

New York senators have introduced a groundbreaking bill to legalize psilocybin-assisted therapy for individuals with qualifying mental health conditions. Spearheaded by Senator Nathalia Fernandez (D) and five co-sponsors, the proposal would allow patients to receive psilocybin treatment in clinical settings or at home if travel is not feasible. Certified facilitators would administer the therapy, with legal protections provided for both patients and facilitators.

The bill also establishes a $5 million Psilocybin Assisted Therapy (PAT) grant program aimed at making treatment accessible to veterans, first responders, and low-income individuals. Additionally, the state’s Department of Agriculture and Markets would oversee a pilot program for cultivating psilocybin mushrooms to reduce costs.

This initiative builds on prior legislative efforts that stalled in committee. Advocates argue that psilocybin offers a promising alternative for addressing the ongoing mental health crisis. Read more about this proposal on Marijuana Moment.

North Dakota Lawmakers Consider Kratom Ban in New Bill

North Dakota legislators are debating a controversial bill that could significantly impact the availability of kratom in the state. House Bill 1218, spearheaded by Representative Zachary Ista, proposes classifying kratom as a Schedule I controlled substance. This move would effectively ban the sale and possession of kratom, a plant-based substance originating from Southeast Asia. Proponents of the bill cite public health concerns, pointing to kratom’s potential for abuse and its psychoactive properties. However, the proposal has sparked debate among kratom advocates who argue for its therapeutic benefits in pain management and mood enhancement. As the bill progresses through the legislative process, it has ignited discussions about the balance between public safety and personal freedom in substance regulation.

New Jersey Medical Board Backs Kratom Protection Act

The New Jersey State Board of Medical Examiners has endorsed S1476, known as the Kratom Protection Act, marking a significant step towards regulating kratom use in the state. This endorsement comes after careful consideration of scientific evidence and expert testimony. The American Kratom Association (AKA) has applauded this decision, viewing it as a crucial move to ensure consumer safety while preserving access to kratom products.

The proposed legislation aims to establish guidelines for kratom manufacturing, distribution, and sale, including age restrictions and labeling requirements. Mac Haddow, Senior Fellow on Public Policy for the AKA, emphasized the importance of this endorsement in protecting consumers from adulterated or contaminated kratom products. The bill, if passed, would position New Jersey as a leader in kratom regulation, potentially influencing similar legislation in other states.